Cargando…

Filgrastim XM02 (Tevagrastim®) after autologous stem cell transplantation compared to lenograstim: favourable cost-efficacy analysis

PURPOSE: Granulocyte colony-stimulating factors (G-CSFs), filgrastim and lenograstim, are recognised to be useful in accelerating engraftment after autologous stem cell transplantation. Several forms of biosimilar non-glycosylated G-CSF have been approved by the European Medicines Agency, with limit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardellini, A, Gigli, F, Babic, A, Andreola, G, Radice, D, Sammassimo, S, Martinelli, G, Laszlo, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694838/ https://www.ncbi.nlm.nih.gov/pubmed/23818939 http://dx.doi.org/10.3332/ecancer.2013.327

Ejemplares similares

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
por: Innocenti, Rolando, et al.
Publicado: (2018)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]
Publicado: (2019)

Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors
por: Farhan, Roiya, et al.
Publicado: (2017)

PB2416: EFFICACY AND SAFETY OF BIOSIMILAR PEGFILGRASTIM AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A COMPARATIVE STUDY WITH BIOSIMILAR FILGRASTIM, LENOGRASTIM AND ORIGINATOR PEGFILGRASTIM
por: Marchesi, Francesco, et al.
Publicado: (2023)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
por: Yoshimura, Hideaki, et al.
Publicado: (2017)

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation
por: Restelli, Umberto, et al.
Publicado: (2020)

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors
por: Schmitt, M, et al.
Publicado: (2013)

Olivetti OPE XM 5220/2
Publicado: (2017)

Production of xylitol and bio-detoxification of cocoa pod husk hemicellulose hydrolysate by Candida boidinii XM02G
por: Santana, Nivio Batista, et al.
Publicado: (2018)

Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
por: Bissett, D., et al.
Publicado: (1995)

AN INHERITED X-LINKED SERUM SYSTEM IN MAN : THE XM SYSTEM
por: Berg, Kåre, et al.
Publicado: (1966)

Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review
por: Markovic, Uros, et al.
Publicado: (2022)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Filgrastim, fibrinolysis, and neovascularization
por: Eton, Darwin, et al.
Publicado: (2022)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
por: del Giglio, A, et al.
Publicado: (2008)

Structure of Vibrio Phage XM1, a Simple Contractile DNA Injection Machine
por: Wang, Zhiqing, et al.
Publicado: (2023)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Filgrastim-Associated Pneumonitis in Cancer Patient Undergoing Hematopoietic Stem Cell (HSC) Mobilization for Autologous-HSC Transplantation
por: Patel, Drashti R, et al.
Publicado: (2020)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122)
por: Jung, Eun Hee, et al.
Publicado: (2023)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Involvement of the capsular GalXM-induced IL-17 cytokine in the control of Cryptococcus neoformans infection
por: LaRocque-de-Freitas, Isabel Ferreira, et al.
Publicado: (2018)

Primary prophylaxis with biosimilar filgrastim cost-effective approach to avoid febrile neutropenia
Publicado: (2021)

Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018
por: Qian, Jingjing
Publicado: (2021)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

Filgrastim therapy in a child with neutropenia induced by linezolid
por: Hernández Segurado, Marta, et al.
Publicado: (2013)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Draft Genome Sequence of Loktanella cinnabarina Strain XM1 Isolated from Coastal Surface Water
por: Ma, Ruijie, et al.
Publicado: (2017)

Is there a role for ‘modified VAD’ in the treatment of multiple myeloma?
por: Agazzi, A, et al.
Publicado: (2009)

Long-term safety of filgrastim (rhG-CSF) administration
por: Confer, Dennis L, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0j07ji8ok340qgsilgpri9lqfl